The first to be discovered were in prostate cancer, where about half of all cases have the TMPRSS2-ERG fusion gene [3,4], and lung cancer, where around 5% of lung cancers have a fusion that activates the ALK tyrosine kinase, the EML4-ALK fusion [5]. Here, ALK is linked to lung cancer.